rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PHAT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Phathom: 3 Key Takeaways for Long-Term Investors
      7h agoYahoo FinancePHAT
      What Comes Next For Phathom Pharmaceuticals After A 65% Slide
      9h agoYahoo FinancePHAT
      Phathom at jefferies global healthcare conference: growth meets access hurdles
      11h agoInvesting.comPHATJEF
      Phathom at guggenheim healthcare innovation conference: gi push gains
      Nov 10Investing.comPHAT
      Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
      Nov 6Yahoo FinancePHAT
      What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide

      Phathom Pharmaceuticals has spent 2026 in the spotlight for very different reasons. On one side, Q3 results showed higher revenue and a smaller loss, and management reaffirmed a target for operating profitability in 2026. For Phathom Pharmaceuticals shareholders, the loss from the start of the year was 63.5%, including dividends. If you were weighing a fresh position after that drop, would the improving cost profile and new VOQUEZNA data justify taking that risk? This theme extends beyond...

      Nov 4Yahoo FinancePHAT
      Phathom Pharmaceuticals to Participate in November Investor Conferences
      Nov 4Yahoo FinancePHAT
      Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
      Nov 3Yahoo FinancePHAT
      H.C. Wainwright reiterates Buy on Phathom stock, $26 target
      Oct 30Investing.comPHAT
      Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second Consecutive ...
      Oct 30Yahoo FinancePHAT
      What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
      Oct 29Yahoo FinancePHAT
      Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Oct 29Yahoo FinancePHAT
      Phathom (PHAT) Q3 2026 Earnings Call Transcript
      Oct 29The Globe and MailPHAT
      Phathom Q3 2026 slides: profitability milestone, 71% revenue growth
      Oct 29Investing.comPHAT
      Earnings call transcript: Phathom beats Q3 2026 EPS forecast as shares rise 8%
      Oct 29Investing.comPHAT
      Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript
      Oct 29BenzingaPHAT
      Phathom Pharma earnings beat by $0.14, revenue fell short of estimates
      Oct 29Investing.comPHAT
      Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
      Oct 29Yahoo FinancePHAT
      Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
      Oct 29Yahoo FinancePHAT
      Phathom Pharmaceuticals Provides Update on FDA Litigation
      Oct 26Yahoo FinancePHAT
      Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity
      Oct 23Investing.comPHAT
      Phathom Pharmaceuticals Faces Legal Challenge Over VOQUEZNA Exclusivity

      Phathom Pharmaceuticals (PHAT) said Friday that BDR Pharmaceuticals International has sued the US Fo

      Oct 23Yahoo FinancePHAT
      PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
      Oct 23Yahoo FinancePHAT
      Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
      Oct 23Yahoo FinancePHAT
      Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

      Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDTFLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 29, 2026, to report its third quarter 2026 financial results and provide a business update. A live webcast and a

      Oct 19Yahoo FinancePHAT
      Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook
      Oct 14Investing.comPHAT
      Phathom to present VOQUEZNA data at gastroenterology meeting
      Oct 8Investing.comPHAT
      Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD
      Sep 29Investing.comPHAT
      Phathom starts phase 3 trial of Voquezna for heartburn relief
      Sep 29Investing.comPHAT
      Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
      Sep 29Yahoo FinancePHAT
      H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)

      Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailPHAT
      Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT)
      Sep 9Seeking AlphaPHAT
      Phathom at Cantor conference: growth, access and new uses
      Sep 9Investing.comPHAT
      PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
      Sep 9Yahoo FinancePHAT
      Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT

      Phathom Pharmaceuticals (PHAT) has an average rating of Buy and mean price target of $23.70, accordi

      Sep 9Yahoo FinancePHAT
      Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

      FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference in New York, NYDate: Wednesday, September 9, 2026Fireside Chat: 10:55 am EDTManagement to par

      Sep 1Yahoo FinancePHAT

      This is the newest page. Registered accounts read further back.